Next-Generation Sequencing (NGS)
Preimplantation Genetic Testing (PGT-A / PGD)
Preimplantation Genetic Testing (PGT) allows our clinical geneticists to analyze the chromosomal and genetic makeup of embryos prior to transfer. By ensuring only genetically healthy (euploid) embryos are transferred, we drastically shorten the time to pregnancy and avoid preventable pregnancy losses.
When is PGT Recommended?
- Advanced maternal age (women aged 35 and older) to screen for numerical chromosomal aneuploidies.
- Couples with a history of recurrent miscarriages (two or more clinical losses).
- Repeated implantation failure after multiple transfers of morphologically good embryos.
- Severe male factor with altered sperm DNA fragmentation or abnormal fish test.
- Couples who are carriers of balanced chromosomal rearrangements (translocations, inversions).
- Carriers of known monogenic hereditary diseases (Cystic Fibrosis, Huntington's, Sickle Cell Disease).
Clinical Advantages of PGT
- Significantly increases the live birth rate per embryo transfer.
- Reduces the risk of first-trimester spontaneous miscarriage by more than 50%.
- Enables elective Single Embryo Transfer (eSET), virtually eliminating high-risk multiple gestations.
- Prevents the transmission of devastating genetic and hereditary disorders to offspring.
- Allows accurate chromosomal gender identification for family balancing or sex-linked conditions.
Important Considerations
- Requires an invasive embryo trophectoderm biopsy at Day 5 blastocyst stage.
- In rare cases, all embryos in a cycle may be diagnosed as aneuploid, resulting in no transfer.
- Cannot repair or correct abnormal embryos; it functions purely as a diagnostic selection tool.
- Additional laboratory cost for Next-Generation Sequencing (NGS).